Skip to main content

Table.4 Logistic regression analysis of factors influencing the SARS-CoV-2 neutralizing antibody immunization

From: Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial

Variables

OR (95% CI)

OR (95% CI)*

GMT ≥ 32

  

 0–14 group

1.0

1.0

 0–21 group

4.1(1.9–8.6)

4.1(1.9–8.8)

 0–28 group

3.5(1.7–7.3)

3.6(1.7–7.6)

GMT ≥ 64

  

 0–14 group

1.0

1.0

 0–21 group

3.5(2.3–5.4)

3.5(2.3–5.4)

 0–28 group

2.7(1.8–4.1)

2.7(1.8–4.1)

GMT ≥ 128

  

 0–14 group

1.0

1.0

 0–21 group

2.7(1.9–3.9)

2.7(1.9–3.9)

 0–28 group

2.3(1.6–3.3)

2.3(1.6–3.4)

GMT ≥ 256

  

 0–14 group

1.0

1.0

 0–21 group

1.8(1.0–3.1)

1.8 (1.0–3.2)

 0–28 group

2.1(1.2–3.7)

2.3(1.3–4.0)

  1. GMT geometric mean titer; CI confidence interval; OR odds ratio
  2. *Adjusted by age, gender, BMI, marital status, education level, influenza vaccination history, smoking, drinking, and chronic diseases